Switching from tamoxifen to exemestane could reduce breast cancer recurrence


Disease-free survival in postmenopausal women with primary breast cancer significantly improved when tamoxifen monotherapy treatment was switched to exemestane therapy after 2-3 years, according to a study published in the New England Journal of Medicine. The existing treatment paradigm calls for tamoxifen, an estrogen-receptor modulator, to be taken alone for all 5 years, but some patients have experienced relapse.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.